Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of Yimitasvir in Healthy Adults
NCT03462173Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Dec 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of yimitasvir in hepatitis C (HCV) (7 cohorts), sponsored by Sunshine Lake Pharma. Primary endpoints: Adverse events, Maximum Plasma Concentration at 144 hours and 3 more. Started Dec 2014; status: completed.
02
Drugs
yimitasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03462173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03462173.